No Data
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results
Marinus Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
D. Boral Capital Maintains Buy on Marinus Pharma, Maintains $3 Price Target
JMP Securities Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating
Hold Rating on Marinus Pharmaceuticals Amid Strategic Uncertainty and TRUST-TSC Study Setbacks
RBC Capital Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating, Cuts Target Price to $1
No Data
No Data